“Zinc and respiratory tract infections: Perspective for COVID-19 (Review)” is an international collaborative review from Germany, Greece, Norway, Russia and USA academies, centers, colleges, hospitals, institutes and universities (Int. J. Mol. Med., 46: 17-26, 2020). In this in-depth review, the authors suggested that modulation of zinc status may be beneficial in COVID-19. The SARS-CoV-2 virus is the cause of the COVID-19 pandemic leading to lung diseases, namely pneumonia, ARDS (very severe pneumonia) and ventilator-induced injuries.
- Zinc works on the mucus lung cells by activating the removal of the virus and also inducing barrier activation, and therefore, the virus is prevented from penetrating deeper inside the body.
- Zinc may prevent viral replication before the viral uncoding and before the viral transcription stages.
- Zinc may boost antiviral activities by upregulating IFNα.
- COVID-19 induces inflammation that aggravates the disease state. Zinc limits excessive inflammatory responses thereby preventing the devastative cytokine storm.
- Bacterial co-infection from viral pneumonia is a commonly high risk. Zinc induces inhibition of Streptococcus pneumonia growth via modulation of bacterial Mn(II) homeostasis.
- High COVID-19 mortality and zinc deficiency share the same risk factors: ageing, immune deficiency and metabolic diseases (obesity, diabetes, atherosclerosis, etc.). The authors concluded that zinc supplementation may have beneficial effects in modulating at least some of the risk factors for high COVID-19 mortality.
Hamari Chemicals, Ltd. is the inventor and manufacturer of a zinc supplement, PepZinGI.
Disclaimer: The text and illustration were composed under fair use law as a summary of a scientific review titled, “Zinc and respiratory tract infections: Perspective for COVID-19 (Review)” published in Int. J. Mol. Med., 46: 17-26, 2020.
Hamari Chemicals, Ltd. and its co-authored Professor Soloshonok and Professor Han was granted the Symmetry 2021 Best Paper Award!
Convenient Asymmetric Synthesis of Fmoc-(S)-6,6,6-Trifluoro-Norleucine.
Symmetry 2019, 11, 578. DOI: 10.3390/sym11040578
In the research article, we reported a simple high-stereoselective and high-yield synthesis method for fluorine-containing unnatural amino acids using the alkylation reaction of Soloshonok-type chiral glycine equivalent.
By establishing an efficient general synthesis method for the title compound, which is one of the important fluorine-containing unnatural amino acids, a stable supply of this unnatural amino acid was achieved. By incorporating this amino acid into peptide synthesis, the manufacture of peptides with antitumor and antibacterial properties were successful. This advancement in synthesis is expected to contribute to the development of new drugs such as fluorine-containing peptide drugs that will dramatically improve enzyme inhibitory activity.
News Release from the Publisher
Hamari would not have the resources to contribute to science and technology by publishing research studies and disclosing new technologies and knowledge in patents without your continued business
Hamari’s List of Publications
Hamari will be closed for the winter break from December 30, 2020 until January 4th, 2021. See you next year!
Hamari Chemicals, Ltd. was invited to present at
the Dietitians Australia 2021 Conference
in July 11-13, 2021.
Functional dyspepsia and Gastro-esophageal reflux disease are two highly prevalent upper GIT disorders, which significantly impair quality of life. Chelated compounds of zinc have demonstrated efficacy for addressing the symptoms and underlying drivers of upper digestive complaints and represent a compelling support to conventional drug therapy. Attendees will understand the evidence for, indications and contraindications for these key clinically trialed nutritional compounds.
Hamari will have a 20 minutes presentation focusing on PepZinGI’s safety and efficacy.
Our US subsidiary, Hamari USA, has relocated its laboratory within the greater Sorrento Valley area. Hamari USA looks forward in continuing to serve you in all of your custom synthesis needs.
11558 Sorrento Valley Road, Suite 3
San Diego, California, 92121, USA
Several review articles on the synthesis of typical active pharmaceutical ingredients using Hamari’s Tailor-Made Amino Acids as starting materials and synthetic intermediates were published.
Applications of fluorine-containing amino acids for drug design.
Eur. J. Med. Chem. 2020, 186, 111826.
Tailor-made amino acids and fluorinated motifs as prominent traits in modern pharmaceuticals.
Chem. Eur. J. 2020, 26, 11349-11390. [Reviews Showcase]
Cyclic tailor-made amino acids in the design of modern pharmaceuticals.
Eur. J. Med. Chem. 2020, 208, 112736.
We, at Hamari Chemicals, Ltd., would like to express our gratitude for having received knowledge, education and support from academia, businesses and society, by sharing our discoveries at various academic societies, and publishing research articles and patents.
Hamari’s list of publications
Hamari will be taking a rest for the summer holidays from August 10 to 14. We will be back on August 17 to serve you even better!
Our headquarter has moved to its new office on July 1,2020.
Due to this relocation, we will change the address on our documents, such as invoices, issued from July 1,2020 as follows:
1-4-29, Kunijima, Higashiyodogawa-ku, Osaka, 533-0024, Japan
1-19-40, Nankokita, Suminoe-ku, Osaka, 559-0034, Japan
The location of our domestic sales and international department at Kitahama, Osaka remains unchanged.
Hamari got published again in ChemistryOpen! It’s really interesting.
Hamari has just completed the registration of several of our tailor-made amino acids in SciFinder!
What is SciFinder? SciFinder is web platform extensively used by universities and research companies to find and obtain rare starting materials for their research. Sci-Finder is owned by the American Chemical Society who is also the owner of CAS numbers.
Now that Hamari Chemicals, Ltd. is registered with SciFinder, we look forward to receiving your orders!
Visit the SciFinder website
One of Hamari’s many research work is in-press in the Organic Process Research Development publication.
A review on Hamari Ligands was published in ACS Omega describing our core technologies and their applications.
Hamari Headquarter in Osaka will be closed on December 10, 2019 to observe our company’s anniversary.
Hamari was at Supply Side West with Hamari USA and our US business partner, Xsto Solutions!
We had a great time and expanded our business horizon.
Supply Side West 2019
Venue: Mandalay Bay, Las Vegas
Date: Oct. 17 – 18, 2019
Won’t you come see us next year?
Chitose Hamari will exhibit at The 14th International Conference on Cutting-Edge Organic Chemistry in Asia (ICCEOCA-14)
(what a mouthful!)
We hope to see you there!
Meet you at CPhI Worldwide 2019 in Frankfurt on Nov. 5 – 7, 2019.
Our Booth 41A41 is in Hall 4.1.
Come mix business with pleasure! Coz’ manufacturing active ingredients is such a blast!
We are the solution to your synthesis problems, your quality management heartaches and your large scale manufacture headaches!
We come from Japan to ESPECIALLY MEET YOU!
Hamari Japan will be closed for the summer holidays from August 10 to 18, 2019. We will be back, tanned and ready for work!
Hamari co-authored a research article on asymmetric synthesis with Professor Vladim Soloshonok, and the article is now published in ACS Omega!
the research articleHamari’s publication list
Hamari co-authored a research article with Professor Vladim Soloshonok on asymmetric synthesis at 100 g scale in Chemistry Open
detailsHamari’s Scientific Publication List
Hamari collaborated with Professor Vadim Soloshonok on a research on the optical resolution of rimantadine. The research is now published in Molecules.
Optical Resolution of Rimantadine
Hamari’s Scientific Publication List